Di Zhe Pharmaceuticals' revenue increased by 294.24% in 2024, with a global innovative pipeline relay layout.

On the evening of April 29th, Dize Pharmaceuticals disclosed its performance in 2024. In 2024, the company achieved operating income of 360 million yuan, a year-on-year increase of 294.24%; net loss attributable to shareholders was approximately 846 million yuan, a year-on-year decrease of 24%. 2024 was the first complete fiscal year in which the company achieved commercialization, with sales revenue reaching 360 million yuan.